英格兰1998-2017年前列腺特异性抗原检测与机会性前列腺癌筛查的队列研究
该开放队列研究基于英格兰QResearch数据库,纳入2 808 477名40-75岁男性,随访至19年,评估前列腺特异性抗原(PSA)检测和机会性筛查的 uptake 及相关因素。研究发现机会性PSA筛查的累积 uptake 在5年、10年和19年分别为9.96%、22.71%和44.13%,并估计CAP试验对照臂的潜在污染率为24.50%。结论指出大量男性参与机会性筛查,可能污染CAP试验结果。
要点
- 机会性PSA筛查累积 uptake 5年9.96%、10年22.71%、19年44.13%。
- 估计CAP试验对照臂潜在污染率为24.50%。
- 尽管疗效与危害不确定,大量男性仍选择机会性筛查。
核心结论
- 英格兰大量男性参与机会性前列腺癌筛查,可能污染CAP试验并影响结果解读。
研究设计与样本
- 开放队列研究,使用QResearch数据库,纳入2 808 477名40-75岁男性,随访至19年。
主要发现
- 631 426名男性共接受1 720 855次PSA检测,其中410 724名男性接受机会性PSA筛查。
- 机会性筛查累积 uptake 5年9.96%、10年22.71%、19年44.13%。
- 估计CAP试验对照臂潜在污染率为24.50%。
临床怎么用
- 全科医生应了解机会性PSA筛查的高 uptake 及其对试验解读的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer is a leading cause of cancer- related death. Interpreting the results from trials of screening with prostate-specific antigen (PSA) is complex in terms of defining optimal prostate cancer screening policy. AIM: To assess the rates of, and factors associated with, the uptake of PSA testing and opportunistic screening (that is, a PSA test in the absence of any symptoms) in England between 1998 and 2017, and to estimate the likely rates of pre-randomisation screening and contamination (that is, unscheduled screening in the 'control' arm) of the UK-based Cluster Randomised Trial of PSA Testing for Prostate Cancer (CAP). DESIGN AND SETTING: Open cohort study of men in England aged 40-75 years at cohort entry (1998-2017), undertaken using the QResearch database. METHOD: Eligible men were followed for up to 19 years. Rates of PSA testing and opportunistic PSA screening were calculated; Cox regression was used to estimate associations. RESULTS: The cohort comprised 2 808 477 men, of whom 631 426 had a total of 1 720 855 PSA tests. The authors identified that 410 724 men had opportunistic PSA screening. Cumulative proportions of uptake of opportunistic screening in the cohort were 9.96% at 5 years', 22.71% at 10 years', and 44.13% at 19 years' follow-up. The potential rate of contamination in the CAP control arm was estimated at 24.50%. CONCLUSION: A substantial number of men in England opt in to opportunistic prostate cancer screening, despite uncertainty regarding its efficacy and harms. The rate of opportunistic prostate cancer screening in the population is likely to have contaminated the CAP trial, making it difficult to interpret the results.
引用
- Clift AK, Coupland CA, Hippisley-Cox J, et al. Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017. Br J Gen Pract. 2021. PMID: 33431381. doi:10.3399/bjgp20X713957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。